Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
About this study
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.
- Condition
- Breast Carcinoma, Lung Carcinoma
- Tested
- Health Education, Health Promotion and Education, Patient Navigation, Survey Administration
- Sponsor
- Jonsson Comprehensive Cancer Center
Who can join
- Age
- 40 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 8
- Minimum age: 40 years
- Maximum age: 80 years
- Study condition: Breast Carcinoma, Lung Carcinoma
- Breast screening \> 40
- Lung screening 50-80
- Male (M) or Female (F)
- Current, former, or never smokers
- Close family or friend with smoking history (in or out of state)
Exclusion 4
- Breast screening \< 40
- Lung screening \< 50 or \> 80
- Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded
- Persons with an active cancer
Where
1 site, 1 recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Potential match only. Final eligibility is determined by the study team.